Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

MAREE Mechanisms of Antibiotic Recalcitrance in ESKAPE pathogens

Coordinator
Universite De Rennes, France
Runs
1 July 2023 to 30 June 2025
Status
Running
EU funding
€196k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101109173

What the project is doing

In the project's own words, from its summary on CORDIS.

Antimicrobial resistance (AMR) is the silent pandemic uprising for the past decades that challenges practitioners to everyday life. In this context, more and more infections have become harder to treat, even in absence of genetic markers for AMR. This phenomenon, called recalcitrance, is related to the ability of susceptible bacteria to overcome antibiotic treatment and to reinitiate infection contributing to antibiotic failures and resistance emergence.

Previous studies have described the involvement of a phenotypic switch leading to recalcitrance but underlying mechanism remain poorly understood. ESKAPE (standing for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) pathogens are the most prevalent causative agents in common recurrent healthcare-associated infections as well as well-known for their multidrug resistant phenotype and are the best candidates to understand recalcitrance.

Hereby, we propose to investigate two of them, E. faecium (Efm) and E. cloacae complex (Ecc) by studying the proteome involved in recalcitrance. To identify any protein and/or pathway of interest, we will (i) identify which stress and bactericidal antibiotic induce recalcitrance both in Efm and Ecc; (ii) evaluate proteome and phosphoproteome of isolated antibiotic-recalcitrant bacteria; and (iii) confirm functionality of candidate proteins/pathways by mutagenesis and phenotypic approaches (in vitro and in cellulo) with the expertise of Prof.

Helaine at Harvard Medical School (HMS) in Boston (secondment). Finding potential protein targets can highlight new candidates to further develop new therapies to overcome the rising of AMR.

Topics

Who is involved

OrganisationCityCountryRole
Universite De RennesRennesFranceCoordinator
Harvard Medical SchoolBostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI